Listen

Description

For years, patients with dry age-related macular degeneration have been told to take their AREDS2 vitamins, check their Amsler grid and wait. In this episode, Jason talks with Dr. Gloria Wu, a retina specialist whose San Jose practice has just started offering Valeda, and Darren, a research assistant in her practice, about a new option for these patients. Valeda is the first FDA-authorized treatment for early to intermediate dry AMD. It uses three wavelengths of low-level light to support stressed retinal cells, and the sessions are painless and non-invasive. Dr. Wu walks through the evidence from the LIGHTSITE III trial, a randomized, double-masked, sham-controlled study of 148 eyes. After two years, treated eyes had gained almost six letters on the eye chart, compared with about one letter in the sham group. They also had about half as much drusen growth, and far fewer developed new geographic atrophy. She also shares the early improvements she's seeing in her own patients, explains who is and isn't a good candidate, and offers some advice for anyone who has been told to wait and watch.